Qureight

Enterprise-Grade Imaging CRO for Clinical Trials

Qureight is a technology-first, AI-powered imaging Contract Research Organization (CRO) that accelerates clinical trials for lung and heart disease therapies. The platform combines automated image management, AI-driven analysis, and precision endpoints to help pharmaceutical companies bring life-saving treatments to market faster.

Who It's For

Designed for biopharma companies conducting interventional clinical trials in respiratory and cardiovascular therapeutic areas, including Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Hypertension (PH), and Bronchiectasis. The platform serves clinical operations teams, data scientists, and medical affairs professionals who need robust, reproducible imaging endpoints.

Core Capabilities

Qureight delivers three integrated product offerings:

• Global Imaging CRO Services: Modern, high-performance platform with workflow tools for rapid site onboarding and patient evaluation in days rather than weeks. Includes radiology coordination, clinical biomarkers, data curation, quality control, and central reads.

• AI-Powered Endpoints and Analytics: Proprietary deep-learning lung image biomarkers (Lung8™, Air8™, Fibr8™, Glass8™, and Vascul8™) purpose-built for tracking treatment response, predicting disease progression, assessing long-term clinical outcomes, and reporting baseline disease severity.

• Data Science Products: Commercial access to large real-world datasets enabling synthetic control arms for trials where placebo groups are impractical or unethical. Supports early drug development, trial design optimization, and toxicity analysis.

Key Differentiators

The platform operates with ISO 13485:2016 and ISO 27001:2022 certifications, is GxP and 21 CFR Part 11 compliant, and provides KOL advisory boards and endpoint discovery services. Qureight's proprietary infrastructure enables more sensitive measurement of fibrosis volume changes and multi-compartment lung quantification, addressing the complex challenges of monitoring diseases that are difficult to diagnose using traditional methods.

Trusted by Leading Biopharma

Customers including Vicore Pharma AB, Avalyn, and Rein rely on Qureight's imaging biomarkers to gain critical insights into patient characteristics, drug effects, and treatment response in their clinical development programs.